Building a New Therapeutic Class
Pet Pharmaceuticals is building a pharmaceutical asset-creation company around a new therapeutic class of pharmaceutical-grade multi-pathway combination phytopharmaceutical medicines.
The Company combines a repeatable scientific capability, a diversified therapeutic portfolio and a capital-efficient commercial model designed to create valuable pharmaceutical assets for strategic partnership, licensing and co-development.
The Investment Thesis
- A differentiated therapeutic approach designed for chronic and complex diseases.
- An Integrated Scientific Discovery Capability capable of generating multiple programmes.
- Six initial therapeutic indications creating portfolio diversification and multiple value-inflection opportunities.
- A lead Parasiticide Programme that has completed in vitro efficacy studies.
- A growing competitive moat built from integrated science, proprietary combinations, protected knowledge and intellectual property.
- A capital-efficient Discover → Develop → Validate → Monetise business model.
- Experienced Board and Advisory leadership across science, development, market access, intellectual property, partnering and governance.
Why Now?
Scientific advances in natural-product characterisation, analytical chemistry, systems biology, pharmaceutical formulation and data science now make it possible to evaluate and develop complex nature-derived combinations with a level of precision and consistency that was previously difficult to achieve.
At the same time, companion-animal healthcare continues to face important unmet needs across chronic disease, long-term tolerability, side effects and therapeutic resistance. Pet Pharmaceuticals is positioned at the intersection of these scientific and market developments.
A Diversified Therapeutic Portfolio
The Company’s six initial programmes address parasiticides, osteoarthritis, dermatitis, lymphoma, diabetes/obesity and anxiety.
This portfolio approach reduces dependence on a single asset while allowing the same scientific capability to generate multiple development and partnering opportunities.
Scientific Progress
The lead Parasiticide Programme has completed in vitro efficacy studies. This milestone provides an important foundation for the next phase of development and demonstrates the Company’s ability to translate its scientific approach into testable pharmaceutical candidates.
The wider portfolio is progressing through programme selection, candidate optimisation and development planning using a disciplined stage-gated framework.
An Integrated and Defensible Capability
Pet Pharmaceuticals’ competitive moat is created through the integration of its PolyNexis+™ Discovery Platform, proprietary nucleus product combinations, protected scientific sources and knowledge, specialist development expertise and growing intellectual property.
This integrated model is more difficult to replicate than a single patent or product and is designed to strengthen as additional programmes, data and proprietary knowledge are created.
A Capital-Efficient Business Model
The Company’s model is to Discover, Develop, Validate and Monetise.
Pet Pharmaceuticals intends to advance programmes through key scientific and preclinical value-inflection points before creating returns through:
- Strategic partnerships
- Programme or territorial licensing
- Co-development agreements
- Platform-enabled discovery collaborations
- Asset monetisation
This approach is designed to create pharmaceutical value without requiring the Company to build the full commercial infrastructure associated with independently taking every medicine to market.
World-Class Leadership
Pet Pharmaceuticals is led by a world-class Board of Directors and supported by an internationally recognised Scientific & Strategic Advisory Board.
The team combines expertise across pharmaceutical development, veterinary medicine, CMC and manufacturing, intellectual property, health economics, market access, regulatory strategy, commercialisation, capital formation and corporate governance.
The Investment Opportunity
Pet Pharmaceuticals is seeking £10.2 million, equivalent to approximately £1.7 million per therapeutic indication, to:
- advance six initial programmes through key preclinical milestones;
- progress the lead Parasiticide Programme;
- strengthen the Integrated Scientific Discovery Capability;
- expand the intellectual-property portfolio;
- generate partner-ready scientific data packages
- support partnership and licensing discussions.
Why Pet Pharmaceuticals Can Create Long-Term Value
- A new therapeutic class with potential application across multiple diseases.
- A portfolio model providing diversification and repeated value-creation opportunities.
- A repeatable scientific capability rather than dependence on a single product.
- A capital-efficient strategy aligned with pharmaceutical partnering and licensing.
- Potential future extension from companion animals into livestock and selected human therapeutic applications.
- Leadership with the experience required to progress scientific innovation into commercially valuable pharmaceutical assets.
Investor Enquiries
Pet Pharmaceuticals welcomes discussions with investors and strategic partners who share the Company’s ambition to create safer, more effective medicines and establish a new therapeutic class.
Please contact the Company to request further investment information or arrange an introductory discussion.
Current Raise
£
0
m
Target Milestones
“We are building an AI-enabled veterinary pharmaceutical platform company.”